1. Home
  2. Directory
  3. Louisiana
  4. Shreveport
  5. Student In An Organized Health Care Education Training Program
  6. NPI Profile
  7. Prescriptions 1659015014

JOSEPH FITZ-GERALD
Prescription History 1659015014
Student in an Organized Health Care Education/Training Program in Shreveport, LA

NPI Status: Active since April 22, 2022

Contact Information

1501 KINGS HWY
SHREVEPORT, LA
ZIP 71103
Phone: (318) 626-2750

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JOSEPH FITZ-GERALD, an active Student in an Organized Health Care Education/Training Program specialist practicing in Shreveport, LA. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 264 documented patient claims. Among these therapy options, the most frequently utilized medication is Tamsulosin Hcl, which accounts for 90 claims alone.

Medication Index

Cephalexin

Generic Formulation: CephalexinSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 17
30-Day Fills 23.0
Days Supply 368
LA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply356
Conservative Utilization

This provider writes prescriptions for this formulation 39.3% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $69.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.07

State Avg Cost Per Claim

$7.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Dutasteride

Generic Formulation: DutasterideSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 19
30-Day Fills 21.0
Days Supply 630
LA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills68.5
Peer Average Days Supply2,035
Conservative Utilization

This provider writes prescriptions for this formulation 44.1% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $303.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.96

State Avg Cost Per Claim

$38.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.

Therapeutic Applications

This medication is used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It works by reducing the size of the enlarged prostate. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate frequently or urgently (including during the middle of the night). It may also reduce the need for surgery to treat BPH. Dutasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. This medication should not be used by women or children.

Finasteride

Generic Formulation: FinasterideSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 65
30-Day Fills 131.0
Days Supply 3,802
LA State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills133.1
Peer Average Days Supply3,941
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $677.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.43

State Avg Cost Per Claim

$14.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.

Therapeutic Applications

Finasteride is used to shrink an enlarged prostate (benign prostatic hyperplasia or BPH) in adult men. It may be used alone or taken in combination with other medications to reduce symptoms of BPH and may also reduce the need for surgery. Finasteride may improve symptoms of BPH and provide benefits such as decreased urge to urinate, better urine flow with less straining, less of a feeling that the bladder is not completely emptied, and decreased nighttime urination. This medication works by decreasing the amount of a natural body hormone (DHT) that causes growth of the prostate. Finasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. Women and children should not use this medication.

Gemtesa

Generic Formulation: VibegronSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 16
30-Day Fills 18.0
Days Supply 540
LA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills41.0
Peer Average Days Supply1,080
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.9% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,220.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$576.30

State Avg Cost Per Claim

$510.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat overactive bladder. Overactive bladder is a problem with how your bladder stores urine that causes a sudden urge to urinate. The urge may be hard to control, and overactive bladder symptoms may include frequent urination, strong sudden urges to urinate, or involuntary loss of urine (incontinence). Vibegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 28
30-Day Fills 39.5
Days Supply 1,105
LA State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills72.9
Peer Average Days Supply2,003
Conservative Utilization

This provider writes prescriptions for this formulation 48.1% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,816.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$636.30

State Avg Cost Per Claim

$558.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Oxybutynin Chloride Er

Generic Formulation: Oxybutynin ChlorideSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 14
30-Day Fills 18.0
Days Supply 540
LA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills74.2
Peer Average Days Supply2,190
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.1% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $189.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.55

State Avg Cost Per Claim

$37.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This is a long-acting form of oxybutynin that is used to treat overactive bladder and urinary conditions. It relaxes the muscles in the bladder to help decrease problems of urgency and frequent urination. Oxybutynin belongs to a class of drugs known as antispasmodics. This medication is also used to treat children 6 years of age and older who have an overactive bladder due to certain nerve disorders (such as spina bifida).

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 72
LA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills29.1
Peer Average Days Supply356
Conservative Utilization

This provider writes prescriptions for this formulation 44.4% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.60

State Avg Cost Per Claim

$5.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 90
30-Day Fills 155.0
Days Supply 4,506
LA State Average Benchmarks
Peer Average Claims96.0
Peer Average 30-Day Fills196.8
Peer Average Days Supply5,816
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $765.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.50

State Avg Cost Per Claim

$14.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JOSEPH FITZ-GERALD provides transparency into local medical care patterns within Shreveport, LA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Student in an Organized Health Care Education/Training Program** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.